Vanda Pharmaceuticals' chief says the company's drug could help with one of the most common GLP-1 side effects. The claim comes from the company.
Recap by typeshit. Full story at Newsmax.
The Washington Post looks at why so many users report shedding, a problem now nicknamed "Ozempic hair," and what new research suggests about the cause.
She says GLP-1 drugs slow how fast the stomach empties. That can let stomach contents reach the lungs during sedation, even after fasting.
The endocrinologist cautions that an interesting effect seen in animals does not mean a compound is suitable for human use.
The account calls the up to 28% weight loss impressive but says only about half of participants finished, citing nausea, constipation and skin sensitivity.
Eli Lilly reports its experimental drug more than doubled Ozempic's weight loss in a phase 3 study of people with diabetes.
AllSci looks at how Eli Lilly's third quarter shaped up, with retatrutide adding weight to its GLP-1 lineup and more cancer drugs moving through development.
Loading…